David F. Claxton - Concepedia

Author

David F. Claxton

Penn State Milton S. Hershey Medical Center ORCID

Also Known As

Arun K. Sharma, Claxton, David F., D Claxton, D F Claxton, D. Claxton, D. F. Claxton, D.C. Claxton, D.F. Claxton, DAVID CLAXTON, DF Claxton

360

Publications

14.8K

Citations

H-Index

114

Concepts

All Affiliations

Penn State Milton S. Hershey Medical Center The University of Texas MD Anderson Cancer Center Pennsylvania State University University of Pennsylvania University of Chicago

About

David F. Claxton is an author at Penn State Milton S. Hershey Medical Center specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	47	2.9K
2	Health Sciences	11	11	541
3	Engineering	4	4	555
4	Natural Sciences	1	1	35
5	Public Health	1	1	49

David F. Claxton

128

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy Sergio Giralt, Elihu H. Estey, Maher Albitar, Blood	1997	1.2K
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Issa F. Khouri, Michael J. Keating, M Körbling, Journal of Clinical Oncology	1998	927
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia Pu Liu, Susan A. Tarlé, A K Hajra, Science	1993	739
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Sergio Giralt, Peter F. Thall, Issa F. Khouri, Blood	2001	570
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Sergio Giralt, Peter F. Thall, Issa F. Khouri, Blood	2001	516
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML AB Deisseroth, Z. Zu, David F. Claxton, Blood	1994	484
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes, The Lancet Oncology Selective InhibitionHematological MalignancyOncologyMedicinePharmacotherapy	2017	484
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 Wendy Stock, Selina M. Luger, Anjali S. Advani, Blood	2019	454
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Haematologica	2018	439
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. Issa F. Khouri, Jorge Romaguera, Hagop M. Kantarjian, Journal of Clinical Oncology	1998	358

Page 1